CytoTronics' Breakthrough Semiconductor Platform Poised to Set New Standard in High-Throughput Phenotypic Screening for Drug Discovery
Retrieved on:
Mardi, décembre 12, 2023
Biotechnology, Technology, Health, Pharmaceutical, Biometrics, Semiconductor, Health Technology, Research, Software, Science, Hardware, Medicine, Cell biology, Engineering, SLAS, Drug design, Nature Communications, Adventitial cystic disease, Neuroscience, Biomedical Research, Wen Xuan, Cardiotoxicity, Drug discovery, Cancer, Society, Cell, Inflammation, Drug development, Laboratory automation, Fibrosis, Mobile phone, Medical imaging, Boston
The CytoTronics semiconductor platform captures an order of magnitude more information per biological sample than previous commercial techniques and will provide scientists with more front-end screening information.
Key Points:
- The CytoTronics semiconductor platform captures an order of magnitude more information per biological sample than previous commercial techniques and will provide scientists with more front-end screening information.
- "Our platform represents a significant advancement in the world of high-throughput phenotypic screening,” stated Jeffrey Abbott, co-founder and CEO of CytoTronics.
- "We believe that our platform has the potential to become an indispensable component of drug discovery and biomedical research,” stated Vince Wu, co-founder and CTO of CytoTronics.
- Applications will include early-stage drug compound screening, downstream toxicity assays, immuno-oncology, and combining the techniques from the paper with electrophysiological measurements for cardiotoxicity and neuroscience applications.